A Phase 1 Open-label Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP0367 Compared to Participants With Normal Hepatic Function
Latest Information Update: 24 Jan 2023
At a glance
- Drugs Bocidelpar (Primary)
- Indications Duchenne muscular dystrophy; Hypoxia; Metabolic disorders; Mitochondrial myopathies
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Global Development
- 04 Feb 2022 Status changed from recruiting to completed.
- 02 Nov 2021 Planned End Date changed from 31 Mar 2022 to 31 Jan 2022.
- 02 Nov 2021 Planned primary completion date changed from 31 Mar 2022 to 31 Jan 2022.